156 related articles for article (PubMed ID: 27357402)
1. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.
He WZ; Rong YM; Jiang C; Liao FX; Yin CX; Guo GF; Qiu HJ; Zhang B; Xia LP
Chin J Cancer; 2016 Jun; 35(1):58. PubMed ID: 27357402
[TBL] [Abstract][Full Text] [Related]
2. A novel scoring system predicting survival benefits of palliative primary tumor resection for patients with unresectable metastatic colorectal cancer: A retrospective cohort study protocol.
Cao G; Zhou W; Chen E; Wang F; Chen L; Chen M; Zhao W; Xu J; Zhang W; Zhang G; Huang X; Song Z
Medicine (Baltimore); 2019 Sep; 98(37):e17178. PubMed ID: 31517873
[TBL] [Abstract][Full Text] [Related]
3. Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis.
Zhang RX; Ma WJ; Gu YT; Zhang TQ; Huang ZM; Lu ZH; Gu YK
World J Surg Oncol; 2017 Jul; 15(1):138. PubMed ID: 28750680
[TBL] [Abstract][Full Text] [Related]
4. Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.
Connell LC; Boucher TM; Chou JF; Capanu M; Maldonado S; Kemeny NE
J Surg Oncol; 2017 Mar; 115(4):480-487. PubMed ID: 28008623
[TBL] [Abstract][Full Text] [Related]
5. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
6. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?
Bakalakos EA; Burak WE; Young DC; Martin EW
Am J Surg; 1999 Jan; 177(1):2-6. PubMed ID: 10037299
[TBL] [Abstract][Full Text] [Related]
7. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
[TBL] [Abstract][Full Text] [Related]
8. Survival outcome of palliative primary tumor resection for colorectal cancer patients with synchronous liver and/or lung metastases: A retrospective cohort study in the SEER database by propensity score matching analysis.
Chen X; Hu W; Huang C; Liang W; Zhang J; Wu D; Lv Z; Li Y; Luo Y; Liang Z; Wang M; Wang J; Yao X
Int J Surg; 2020 Aug; 80():135-152. PubMed ID: 32634480
[TBL] [Abstract][Full Text] [Related]
9. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative-intent hepatectomy for colorectal liver metastases: A two-center cohort study.
Bai L; Lin ZY; Lu YX; Chen Q; Zhou H; Meng Q; Lin CP; Huang WL; Wan YL; Pan ZZ; Wang DS
Cancer Med; 2021 Nov; 10(22):8005-8019. PubMed ID: 34636145
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
12. Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients.
Gresham G; Renouf DJ; Chan M; Kennecke HF; Lim HJ; Brown C; Cheung WY
Ann Surg Oncol; 2014 Nov; 21(12):3917-23. PubMed ID: 24859937
[TBL] [Abstract][Full Text] [Related]
13. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
14. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
[TBL] [Abstract][Full Text] [Related]
16. Benefit of primary tumor resection in stage IV colorectal cancer with unresectable metastasis: a multicenter retrospective study using a propensity score analysis.
Ishihara S; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Hata K; Nozawa H; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Sugihara K; Watanabe T
Int J Colorectal Dis; 2015 Jun; 30(6):807-12. PubMed ID: 25922146
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
[TBL] [Abstract][Full Text] [Related]
19. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
20. The use of the major anoxic stress response protein P34, the K isozyme of lactate dehydrogenase, and carcinoembryonic antigen in the follow-up of patients with colorectal adenocarcinoma.
Petrelli NJ; Hanna S; Rodriguez-Bigas M; Anderson G
Cancer; 1992 Oct; 70(7):1834-7. PubMed ID: 1525757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
